Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 65 to 90

Effects of low-dose esmolol on heart injury in elderly patients after surgery

Official title: Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients:A Multicenter, Prospective, Double-blind, Randomized Controlled Study

Run by Qianfoshan Hospital · NCT05635877 · Data updated 2026-11-12

This study is testing whether giving low-dose esmolol to older patients before non-heart surgery can help reduce heart injury compared to a placebo.

More Frailty trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages65 Years to 90 Years
SexAll
Enrollment2000 (estimated)
SponsorQianfoshan Hospital
Academic / other
Locations1 site (Jinan, Shandong)
StatusRecruiting
StartedFebruary 7, 2023
Main results expectedNovember 30, 2026
Study endsDecember 30, 2026
Registry record updatedMarch 29, 2023
Trial IDNCT05635877 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are elderly patients aged 65 and older with a modified frailty index of 0.21 or higher who are scheduled for non-cardiac surgery.

Probably not a fit

Patients with a history of myocardial infarction, significant cardiac insufficiency, or severe lung disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the relationship between preoperative frailty and myocardial injury in elderly patients undergoing non-cardiac surgery. It aims to identify predictive factors for myocardial injury and evaluate the impact of low-dose esmolol on reducing such injuries. Esmolol, a selective β-adrenergic receptor blocker, is administered to manage heart rate and reduce myocardial oxygen consumption during the perioperative period. The study will compare outcomes between patients receiving esmolol and those receiving a placebo.

Why it matters

Potential benefit: If successful, this study could lead to improved cardiac outcomes and reduced myocardial injury in frail elderly patients undergoing non-cardiac surgery.

How similar studies have gone: Previous studies have shown promising results for the use of β-blockers like esmolol in reducing perioperative myocardial ischemia, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 65 years;
2. ASA: ⅰ-ⅳ;
3. Modified frailty index (mFI) ≥ 0.21;
4. Patients undergoing non-cardiac surgery.

Exclusion Criteria:

1. Refuse to participate;
2. Expected hospital stay \<3 days;
3. Preoperative β-blocker therapy;
4. History of myocardial infarction or coronary artery disease;
5. Preoperative bradycardia (heart rate \[HR\] \< 50 bpm) or arrhythmia;
6. Significant cardiac insufficiency (i.e., pulmonary artery pressure \>18 mm Hg, cardiac index ≤ 2.2 L/min/m 2);
7. Severe valvular heart disease;
8. Severe lung disease (e.g. asthma or chronic obstructive pulmonary disease);
9. Patients with perioperative troponin elevation due to nonischemic causes (e.g., sepsis, pulmonary embolism, arrhythmia);
10. The same patient can only be included once, regardless of whether the reason for the second operation is related to the first cause.

    \-

Where it's running

  • Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University
    Jinan, Shandong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.